Kaya Holdings Inc (QB) (KAYS) 시세

$KAYS Kaya Holdings, Inc. (OTCQB:KAYS): The Sacred Mushroom, Oregon's Premier Psilocybin Treatment Center Introduces "Synergy by Design" Journey Customization Program


https://www.accessnewswire.com/newsroom/en/agriculture/kaya-holdings-inc-otcqbkays-the-sacred-mushroom-oregons-premier-psilocybin-treatment-center-introduces-synergy-by-design-journey-customization-program-969432

PORTLAND, OR / ACCESS Newswire / January 16, 2025 / Kaya Holdings, Inc. (OTCQB:KAYS) and The Sacred Mushroom™ ("TSM"), Portland's one-of-a-kind psilocybin treatment center today announced the launch of "Synergy by Design," a revolutionary program that empowers individuals to curate deeply personal and transformative psychedelic journeys. By combining intention, sensory customization, and meaningful activities, this program is designed to ensure that every participant's experience reflects their unique needs, preferences, and goals.

The Sacred Mushroom™, at 11,000 sq. ft., has been purposely curated to provide every TSM guest with the full transformative potential of the psychedelic journey. Guests can access their perfect setting through TSM's proprietary "Synergy by Design" and interact with journey-enhancing activities such as art expression, body movement, and journaling.

What is Synergy by Design?

Synergy by Design is a framework rooted in personalization and empowerment, offering participants the tools to craft their own transformative psilocybin journeys. Each step invites individuals to align their surroundings, activities, and intentions to create meaningful experiences.

With Synergy by Design, The Sacred Mushroom™ guest can select their surroundings, creating a sensory environment that aligns with their goals by customizing:

Space: Guests choose from serene settings like a quiet nook, lush indoor garden, or private room for maximum comfort and inspiration.

Sounds: Music or ambient sounds, with options including live musicians, curated playlists, or nature's calming white noise.

Scents: Essential oils, herbal infusions, or natural room fragrances to complete the sensory palette.

Synergy By Design further provides activities for guests to tailor to enhance their experience:

Creative Expression: Painting, journaling, crafting, clay sculpturing, kinetic sand, and musical instruments provided.

Mind-Body Connection: An area reserved for yoga, meditation, or body movement exercises.

"At The Sacred Mushroom™, we believe every individual deserves a journey that reflects their unique spirit and aspirations," said Bryan Arnold, Chief Facilitator at The Sacred Mushroom™. Synergy by Design's objective is to ensure that every detail is curated to support our guest."

KAYS CEO Statement

"This unique program is possible because of the size of our facility and our commitment to transform the space into the absolutely ideal psilocybin treatment setting," stated KAYS' CEO Craig Frank. "Synergy By Design is the next step toward achieving the experience we seek to provide, enabling the guest to construct their own visual, auditory and olfactory inputs. It is the ultimate in crafting a personal psilocybin journey. This program is yet another example of how The Sacred Mushroom™ is pioneering psychedelics and setting the stage for change in the $82.47 billion mental healthcare sector".

$KAYS Kaya Holdings, Inc. and the Sacred Mushroom(TM) Psilocybin Treatment Facility Announce Inaugural Open House and New Series of Low-Dose Psilocybin Sessions


https://www.accesswire.com/958899/kaya-holdings-inc-and-the-sacred-mushroom-tm-psilocybin-treatment-facility-announce-inaugural-open-house-and-new-series-of-low-dose-psilocybin-sessions

PORTLAND, OR / ACCESSWIRE / December 23, 2024 / Kaya Holdings, Inc. (OTCQB:KAYS) and The Sacred MushroomTM, Portland's one-of-a-kind psilocybin treatment center, are excited to announce their first Open House event to be held on Friday, December 27, 2024, from 5:00 PM to 8:00 PM.

This event offers the community a unique opportunity to explore our state-of-the-art facility, meet the team, and learn about the transformative potential of psilocybin-assisted therapies.

To get tickets to the event please access the following link:

https://www.eventbrite.com/e/the-sacred-mushroom-open-house-tickets-1116887333079?aff=oddtdtcreator

During the Open House, attendees will have the chance to tour private treatment rooms, experience the indoor garden, and discover the many activities offered, including art and musical expression, body movement, and mindfulness practices. The Sacred MushroomTM emphasizes the importance of a curated setting, providing a safe and enriching environment for personal growth and healing. Whether you're curious, exploring options for yourself or a loved one, or simply seeking a moment of relaxation, this open house is a perfect opportunity to unwind, connect, and explore what we offer.

As part of its mission to foster deeper connections and healing through creativity and introspection, The Sacred MushroomTM is also thrilled to announce the launch of its "Community, Culture, and a Touch of Psilocybin" series. These group sessions, centered around low-dose psilocybin experiences, will celebrate the works of respected musicians, authors, poets, and visual artists. Each session is designed to blend artistic appreciation with guided introspection, creating a space for participants to explore while building community bonds.

Bryan Arnold, Chief Facilitator of The Sacred MushroomTM, shared: "We are committed to making psilocybin therapy accessible and impactful. With our new series, we aim to merge the transformative power of psilocybin with the inspiration of art, music, and literature to foster growth, healing, and connection."

Attendees of the Open House will receive exclusive details about upcoming sessions in the series and have the opportunity to reserve spots at a special introductory rate. The public (over age 21) is invited to visit The Sacred MushroomTM at 321 SW Glisan Street in Old Towne Portland on December 27 to experience The Sacred Mushroom'sTM revolutionary approach to psilocybin therapy and learn more about how art and culture can intersect with personal transformation.

Titled "Is Psilocybin Right for You?", the e-book details the therapeutic benefits psilocybin can offer to people with mental health concerns or those simply curious. To access a copy of our e-book "Is Psilocybin Right for You?", please click on the above image or go to:

https://thesacredmushroompdx.com/e-book-library/

Once you have accessed the site you can read the book online or download it to be read later offline.

Topics addressed in the book include: What is Psilocybin, How Does Psilocybin Affect the Brain, History of Psilocybin, Is Psilocybin Treatment Right for You, Psilocybin & Personal Growth, Psilocybin & Happiness, Psilocybin & Inner Peace, Psilocybin & Creativity, Psilocybin & Post Traumatic Stress Disorder, Psilocybin & Depression, Psilocybin & Obsessive-Compulsive Disorder, Psilocybin & Sexual Trauma, Psilocybin & Anxiety, Psilocybin & Substance/Alcohol Abuse & Addiction, Psilocybin & Eating Disorders, Psilocybin & Alzheimer's Disease, Psilocybin & End of Life Anxiety, Psilocybin & Cluster Headaches, Understanding Dosing, Risks, The Importance of Integration, and Exploring the Power of Psilocybin at The Sacred MushroomTM.

About The Sacred MushroomTM (https://thesacredmushroompdx.com)

The Sacred Mushroom™ is a legally licensed psilocybin treatment center authorized by the State of Oregon to administer psilocybin treatments within the regulations set forth by the Oregon Health Authority.

$KAYS The Sacred Mushroom(TM) Psilocybin Center Operated by Kaya Holdings, Inc. (OTCQB:KAYS) Releases First E-Book

https://www.accesswire.com/926572/the-sacred-mushroomtm-psilocybin-center-operated-by-kaya-holdings-inc-otcqbkays-releases-first-e-book

"Is Psilocybin Right for You" is the first in a planned series of helpful e-books about psilocybin.

FT. LAUDERDALE, FL / ACCESSWIRE / October 2, 2024 / The Sacred Mushroom™ ("TSM"), an emerging leader in the delivery of psilocybin experiences at its Portland, Oregon facility, announced the release of its first in a series of planned e-books on psilocybin and related issues.

Titled "Is Psilocybin Right for You?", the e-book details the therapeutic benefits psilocybin can offer to people with mental health concerns or those simply curious.

To access a copy of our e-book "Is Psilocybin Right for You?", please click on the image above or go to https://thesacredmushroompdx.com/is-psilocybin-right-for-you-tsm/. Once you have accessed the site you can read the book online or download it to be read later offline.

Topics addressed in the book include: What is Psilocybin, How Does Psilocybin Affect the Brain, History of Psilocybin, Is Psilocybin Treatment Right for You, Psilocybin & Personal Growth, Psilocybin & Happiness, Psilocybin & Inner Peace, Psilocybin & Creativity, Psilocybin & Post Traumatic Stress Disorder, Psilocybin & Depression, Psilocybin & Obsessive-Compulsive Disorder, Psilocybin & Sexual Trauma, Psilocybin & Anxiety, Psilocybin & Substance/Alcohol Abuse & Addiction, Psilocybin & Eating Disorders, Psilocybin & Alzheimer's Disease, Psilocybin & End of Life Anxiety, Psilocybin & Cluster Headaches, Understanding Dosing, Risks, The Importance of Integration, and Exploring the Power of Psilocybin at The Sacred Mushroom™.

For more information or to make an appointment for psilocybin services at The Sacred Mushroom™, please go to https://tsmpdx.com or send an email to info@tsmpdx.com

CEO Statement
KAYS CEO Craig Frank comments on the release of "Is Psilocybin Right for You?", "This e-book, and the others we have planned in the series, bring to a broader audience the information they need to make an informed choice with regard to newly available psilocybin journeys. We welcome everyone seeking to experience the transformative journeys psilocybin can bring. We hope this e-book, and the others that follow, will add to the conversation'

Good Morning $KAYS

$KAYS New Psilocybin center featured on KATU News! (VIDEO)

https://katu.com/news/local/willamette-week-psilocybin-center-piloting-new-business-plan

LOL

Thanks for the chuckle......

Low float monster $KAYS

Good Morning $KAYS

$KAYS New Psilocybin center featured on KATU News! (VIDEO)

https://katu.com/news/local/willamette-week-psilocybin-center-piloting-new-business-plan

Nice start here $KAYS #Shrooms

$KAYS Willamette Week: Psilocybin center piloting new business plan

https://katu.com/news/local/willamette-week-psilocybin-center-piloting-new-business-plan

PORTLAND, Ore. (KATU) — There is a new take on legalized tripping.

A Portland shroom shop is going big, offering trips for corporate retreats, Halloween and even the Super Bowl!

Freelance journalist for Willamette Week, Grant Stringer, joined KATU's Wright Gazaway on Wednesday to talk about the issue.

https://www.wweek.com/news/2024/08/21/a-new-portland-shroom-service-center-offers-halloween-trips-and-bargain-priced-psychedelic-stock/

Good Morning $KAYS

$KAYS ~ Oregon's Premier Psilocybin Center Now Open , The Sacred Mushroom

https://www.dropbox.com/scl/fi/xikstm3vqz2j6g8xt8r7h/KAYS-and-The-Sacred-Mushroom-2024-08-15.pdf?rlkey=p10hh5kwhp19qo63u5kjlhfur&e=1&st=m9134ebl&dl=0

$KAYS New today: https://t.co/qca8BneM9V— Kaya Holdings (OTCQB:KAYS) (@KayaHoldings) August 13, 2024

Good Morning $KAYS

$KAYS 10-Q out! https://www.otcmarkets.com/filing/html?id=17764346&guid=n3O-kqbsRiNaJth

For a detailed power point overview of The Sacred Mushroom™, please click on the above image or the following link: https://storage.googleapis.com/accesswire/media/860189/kaya-holdings-investor-presentation.pdf

https://storage.googleapis.com/accesswire/media/860189/kaya-holdings-investor-presentation.pdf

$KAYS received its Psilocybin Service Centerlicense from the Oregon Health Authority
(“OHA”) to operate The Sacred
Mushroom™ - making KAYS the first U.S.
publicly traded company to own and
operate a U.S. based psychedelic treatment
center.
https://finance.yahoo.com/news/kaya-holdings-awarded-psilocybin-center-123000569.html

Good Morning $KAYS

Tiny Float $KAYS under 6mm float

$KAYS ---> https://thesacredmushroompdx.com/

Good Afternoon $KAYS

$KAYS Kaya Holdings, Inc. (OTCQB:KAYS) Criticizes FDA Rejection of MDMA Therapy for PTSD, Proposes Psilocybin as Alternative Treatment


https://www.accesswire.com/900068/kaya-holdings-inc-otcqbkays-criticizes-fda-rejection-of-mdma-therapy-for-ptsd-proposes-psilocybin-as-alternative-treatment

FT. LAUDERDALE, FL / ACCESSWIRE / August 13, 2024 / Kaya Holdings, Inc., ("KAYS" or the "Company") (OTCQB:KAYS), a "mind care" company with operations in the emerging psilocybin treatment sector and in medical/recreational cannabis, criticized the FDA ruling rejecting MDMA (Ecstasy) therapy as a treatment for PTSD. KAYS, which provides psilocybin treatment services at its Portland, Oregon facility, The Sacred Mushroom ™ proposes consideration of psilocybin therapy as an alternative treatment for PTSD and welcomes anyone seeking psilocybin treatment for PTSD, as permitted by Oregon law.

The Sacred Mushroom ™
The Sacred Mushroom™ is a legally licensed psilocybin treatment center authorized by the State of Oregon to administer psilocybin treatments within the regulations set forth by the Oregon Health Authority ("OHA").

The Sacred Mushroom™, at 11,000 sq. ft., has been purposely designed to provide every TSM guest with the full transformative potential of the psychedelic journey offered by psilocybin. Guests can access their perfect setting through TSM's proprietary "Synergy by Design" and interact with journey-enhancing activities such as art expression, body movement, and journaling.

CEO Statement
Craig Frank, KAYS' CEO responded to the FDA's rejection of MDMA decision, saying, "We are deeply sorry the FDA has decided against MDMA use for the treatment of PTSD and regret the impact this may have on developing a PTSD treatment needed by so many, including numerous military veterans. It is our view that psilocybin, whose use has been authorized by the state of Oregon, offers a potential alternative for treating PTSD, and we invite researchers, organizations and individuals previously focused on using MDMA as a treatment for PTSD, to consider psilocybin treatment and view The Sacred Mushroom™ as a safe, legal space where psilocybin may be administered in a comfortable, welcoming setting."

Psilocybin as a potential alternative to MDMA as a treatment for PTSD
Emerging research has shown that psilocybin can have lasting therapeutic effects after just one or two sessions. A study published in the Journal of Psychopharmacology found that psilocybin-assisted therapy reduced symptoms of depression and anxiety in patients with life-threatening cancer, which often includes PTSD-like symptoms. Another study in Nature Medicine demonstrated that psilocybin-assisted therapy led to significant and sustained improvements in PTSD symptoms in a cohort of military veterans. The effects were particularly noted in the reduction of avoidance behaviors and hyperarousal, which are key components of PTSD.

These published studies, along with additional studies at Kings College, London and John Hopkins University in Baltimore have allowed a comparison of MDMA and psilocybin on matters of efficacy and duration, side effects, and safety profiles. A summary of the comparison reveals:

The time of a psilocybin experience is typically longer than the MDMA experience, and this more prolonged session could provide more time for psychological processing and integration of insights gained during the experience.

While psilocybin typically produces a more introspective and insightful experience with visual and auditory hallucinations, MDMA typically enhances one's feelings of empathy and connection to others without hallucinations. The introspective nature of the psilocybin experience may facilitate deeper psychological integration compared to the shorter-lasting effects of MDMA.

The side effects of psilocybin generally milder than those of MDMA, which include changes in heart rate, dehydration, jaw clenching, nausea, anxiety and agitation, sweating and chills.

Psilocybin has a preferred safety profile with regard to potential for abuse and risk of developing a dependency, compared to MDMA.

You really shouldn't insult jokes unless that was a joke.

This company is a joke.

I found this board because of this ad but there are no posts recently. Is anyone else seeing these ads?

https://ih.advfn.com/stock-market/USOTC/kaya-qb-KAYS/stock-news/90252895/kaya-holdings-inc-psychedelics-subsidiary-taps-t

Finally unloaded this garbage. Needed the write off.

https://reporter.am/2022/12/10/head-to-head-contrast-acerus-pharmaceuticals-otcmktstrlpf-versus-kaya-otcmktskays.html

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC FILE NUMBER 333-177-532
CUSIP NUMBER 0215X109
 
(Check One): [ ] Form 10-K [_] Form 20-F [X] Form 10-Q [_] Form 10-D [_] Form N-SAR
 
For Period Ended: September 30, 2022
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:      
 
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
.PART I -- REGISTRANT INFORMATIONKaya Holdings, IncFull Name of RegistrantFormer Name if Applicable
915 Middle River Drive Suite 316
Address of Principal Executive Office (Street and Number)Fort Lauderdale, FL 33304City, State and Zip Code
 
PART II -- RULES 12B-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
[x](a)  The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;(b)  The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and(c)  The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

PART III--NARRATIVE
State below in reasonable detail why forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Registrant requires additional time to complete the preparation of its financial statements for the quarter ended September 30, 2022, have them properly certified by the executive officers and have them reviewed by its independent auditors. The Registrant will file the Form 10-Q by the fifth calendar day following the required filing date, as prescribed in Rule 12b-25.
PART IV--OTHER INFORMATION
(1)Name and telephone number of person to contact in regard to this notificationCraig Frank561210-5784(Name)(Area Code)(Telephone Number)
 
(2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
[x] Yes [_] No
 
(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
[_] Yes [x] No
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. 
Kaya Holdings, Inc.(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
DateNovember 14, 2022By/s/ Craig Frank
 
INSTRUCTION: The form may be signed by an executive officer or the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

Why bother....

As always.

Filing that 10Q will be late.

POWERBALL BY A MILE!!!!!!!!!!!!!

What's a better pick? KAYS or POWERBALL?

Yes. Total crap.

KAYS is garbage.

https://reporter.am/2022/10/20/head-to-head-comparison-generation-bio-nasdaqgbio-versus-kaya-otckays.html

$1.56 Ask. Yeah baby. Ha ha ha ha ??

https://m.marketscreener.com/quote/stock/KAYA-HOLDINGS-INC-120792914/news/KAYA-HOLDINGS-INC-Management-s-Discussion-and-Analysis-of-Financial-Condition-and-Results-of-Oper-41375941/

Been holding for years. The rise is coming soon.

That's because it is after hours - ask is now $0.109 and so on.

https://www.yahoo.com/now/kaya-holdings-seek-licenses-first-124500117.html

Wow. Ask price 69 cents.

https://www.accesswire.com/710649/Kaya-Holdings-to-Seek-Licenses-for-First-Ever-State-Legal-Psilocybin-Manufacturing-and-Facilitation-Service-Centers-in-Oregon

https://finance.dailyherald.com/dailyherald/article/accwirecq-2022-8-3-kaya-holdings-to-seek-licenses-for-first-ever-state-legal-psilocybin-manufacturing-and-facilitation-service-centers-in-oregon

https://www.benzinga.com/markets/cannabis/22/07/27986532/marijuana-company-kaya-receives-license-for-medical-cannabis-facility-in-epidaurus-greece

10K out - Whooooooopie

https://www.otcmarkets.com/filing/html?id=15735283&guid=sVewkK1wYu52B3h